A note from the editors regarding the magazine, webcasts and other activities.
Like everyone, the staff of Pharmaceutical Executive and our parent company MJH Life Sciences is pivoting to address the current needs of our readers and clients.
If you are one of our print subscribers, we realize that if you receive the monthly publication at your workplace, you might not receive it. So we will deliver the digital version/PDF to you via email, if we have your email. Please note that your issues will still be delivered to you via postal mail, and will be awaiting your return to the office. If you wish to change your delivery address, or delivery preference, you can do so via our online subscription form.
If you are a regular webcast viewer, please note they are still the most popular form of learning right now. Our sister brands at LCGC and Spectroscopy are addressing COVID-19 concerns in the lab. Please note, all of our webcasts are available OnDemand, so if you have missed any, you can go back and watch.
More webinars were launched this week to our healthcare audience, including “Managing Lung Cancer Patients Through the COVID-19 Pandemic: What to Know” on the MJH Life Sciences OncLive brand.
The MJH Life Sciences teams also converted two live full-day, multi-speaker CME-accredited meetings to digital formats within a 48 hour time frame, and we now have a virtual format for dinner events or summits, which is particularly important to the pharma companies used to working in-person. You can reach our business development team if you want to discuss.
And, as always, you can reach the editors directly at their emails with news, articles or questions.
Remember to visit us on LinkedIn, Twitter, Instagram or Soundcloud for our latest information, COVID or otherwise.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
FDA Approves Hikma’s Generic GLP-1 Agonist for Type 2 Diabetes
December 24th 2024Approval marks the first generic version of liraglutide injection, referencing Victoza, for improving glycemic control in adults and children aged 10 years and older with type 2 diabetes, alongside diet and exercise.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.